Date: 2012-12-17
Type of information: Joint-venture agreement
Compound:
Company: SpePharm Holding (The Netherlands) Norgine BV (The Netherlands)
Therapeutic area:
Type agreement: joint-venture
Action mechanism:
Disease:
Details: Norgine BV and SpePharm Holding BV have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene®, MuGard®, Xerotin®, PROther® and the Dantrium® brands. The new joint venture will commercialise this entire product portfolio through Norgine’s pharmaceutical infrastructure, which spans all of the major markets of Europe.
SpePharm AG will seek to acquire further hospital based products which will also be sold through Norgine’s commercial infrastructure. As a consequence of the transactions, TVM Capital and Signet Healthcare Partners announced that SpePharm has repaid all of its existing debt facilities and the two firms have acquired all shares previously owned by the debt providers.
Finally, Norgine BV has acquired the commercial subsidiaries of SpePharm Holding BV in Italy, Germany, the Nordics and the UK. These acquisitions will enable Norgine to enlarge its existing European commercial infrastructure and to fully support the combined product portfolio.
Financial terms: Financial terms were not disclosed.
Latest news:
